Document Detail

Dilated Cardiomyopathy.
MedLine Citation:
PMID:  11696265     Owner:  NLM     Status:  Publisher    
The management of patients with dilated cardiomyopathy (DCM) heart failure starts with the determination of the underlying diagnosis, definition of the hemodynamic character (eg, systolic, diastolic, valvular, right- and left-sided heart dysfunction), recognition of complicating factors (eg, atrial fibrillation, renal dysfunction), and consideration for any surgically remedial lesions (eg, severe valvular regurgitation, high-grade coronary artery occlusive disease). Angiotensin-converting enzyme inhibitors, beta-blocking agents, digoxin, and judicious diuretic administration make up the therapeutic plan for patients with symptomatic DCM heart failure. Angiotensin-converting enzymes are indicated for patients with DCM who have mild or no detectable symptoms; whether this subgroup would benefit from long-term beta-blockade remains to be established. Spirolactone also has been shown to be effective in patients with more advanced stages of heart failure. Biventricular pacing (cardiac resynchronization therapy) recently has been approved for use in patients with DCM and a left ventricular or intraventricular conduction defect and a QRS duration of longer than 140 msec. More intense pharmacotherapy, mechanical devices, and transplantation are directed at patients with severely symptomatic end-stage DCM. The effectiveness of any heart failure treatment plan is very much dependent on nonpharmacologic approaches, including dietary measures, exercise conditioning, and similar considerations, all of which are best delivered by dedicated heart failure programs.
Carl V. Leier
Related Documents :
12640965 - New advances and novel treatments in heart failure.
17363065 - Levosimendan: beyond its simple inotropic effect in heart failure.
6338075 - Vasodilator therapy for acute myocardial infarction and chronic congestive heart failure.
16239825 - The role of endothelin in heart failure.
16996855 - A double-blind, randomized, placebo-controlled multicenter clinical trial to evaluate t...
1746475 - Coronary adrenergic hyperreactivity in patients with syndrome x and abnormal electrocar...
Publication Detail:
Journal Detail:
Title:  Current treatment options in cardiovascular medicine     Volume:  3     ISSN:  1534-3189     ISO Abbreviation:  Curr Treat Options Cardiovasc Med     Publication Date:  2001 Dec 
Date Detail:
Created Date:  2001-Nov-6     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9815942     Medline TA:  Curr Treat Options Cardiovasc Med     Country:  -    
Other Details:
Languages:  ENG     Pagination:  451-462     Citation Subset:  -    
Division of Cardiology, Heart-Lung Research Institute, The Ohio State University Medical Center, 473 West 12th Avenue, Room 261, Columbus, OH 43210, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Lipids and risk assessment.
Next Document:  Idiopathic Giant Cell Myocarditis.